ReviewAdvances in experimental medicine and biology2026
Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases are widespread causes of morbidity and mortality throughout the world. Nanomedicine is at the scale of biomolecular interfaces, the same scale as the development of plaques, thrombi, or misfolded proteins. A variety of nanomaterials, polymeric delivery tools, and engineered biologics have been developed to target and detect or treat the molecular causes of disease at the cellular level. In some cases, these nanostructures have been engineered to bypass immune recognition and deliver therapeutic cargoes. Targeted nanomaterial transport is also assistive technology for diagnostic imaging in cardiovascular disease. Selective localization of contrast agents for ultrasound, magnetic resonance, X-Ray, and optical imaging strategies enables disease-focused contrast. Continued nanomedicine research aims to produce highly specified and highly effective treatments for cardiovascular diseases, alongside enhancing point-of-care diagnostics. As these two sides of medicine progress, therapeutics and diagnostics meet at the nanoscale to create multifunctional image-enhancing and image-enhanced therapeutic tools against cardiovascular disease.
Indexed as
Identifiers
42420710What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.